All Stories

  1. Preclinical In Vitro Evaluation of an Innovative Nutraceutical Mixture Modulating the Histamine H1 Receptor—Preliminary Data
  2. Isolated Hypoglossal Nerve Palsy Associated with Internal Carotid Artery Dissection: A Systematic Review
  3. Severe Chronic Rhinosinusitis with Nasal Polyps: From IL-5–Driven Pathogenetic Mechanisms to Clinical Management in the Italian Clinical Setting
  4. Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial
  5. Development and Evaluation of a Radiomics-Based 3D Volumetric and Densitometric Tomographic Scoring System for Chronic Rhinosinusitis with Nasal Polyposis: A Comparative Analysis
  6. Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR)
  7. Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR
  8. Real‐World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)
  9. The Oral Microbiota: Implications in Mucosal Health and Systemic Disease—Crosstalk with Gut and Brain
  10. The Sinonasal Microbiome in ENP
  11. Evaluation of the Antihistamine and Anti-Inflammatory Effects of a Nutraceutical Blend Based on Quercetin, Perilla frutescens, Boswellia serrata, Blackcurrant, Parthenium, Helichrysum, Lactobacillus acidophilus and Bifidobacterium animalis Through In V...
  12. Influence of Multiple Prior Endoscopic Sinus Surgeries on Dupilumab Efficacy Including Smell Function in the DUPIREAL Population
  13. Dupilumab-Induced Blood Eosinophilia in Patients With Chronic Rhinosinusitis With Nasal Polyps: Temporal Trends and Correlation With Adverse Events
  14. Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)
  15. Two‐Year Turning Point With Dupilumab in CRSwNP: Control, Remission, and Tapering Dosage
  16. Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience
  17. Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review
  18. Patient-Specific Factors to Differentiate Between Branchial Cleft Cysts and CUP Syndrome: A 10 Year Unicenter Study
  19. Defining two dimensional transthoracic echocardiographic aorta dimension reference ranges in healthy subjects: a machine learning based model
  20. The Emerging Role of MicroRNAs in Nasal Inflammatory Diseases and Tumors: From Bench to Bedside
  21. Pilot Study on the Efficacy of a Novel Questionnaire for Assessing Psychological Health in Patients with Chronic Rhinosinusitis with Nasal Polyps Treated with Biologics
  22. Narrative Review of Genetic and Immunological Mechanisms Involved in the Pathogenesis of Kimura’s Disease: New Therapeutic Targets
  23. Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)
  24. Pre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics
  25. Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)
  26. Allergic Rhinitis in Professional Singers: A Monoinstitutional Series
  27. Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab
  28. Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study
  29. Kurzfristige Lebensqualitätsbewertung nach Nasennebenhöhlenoperation bei chronischer Rhinosinusitis
  30. Open-door extended endoscopic transorbital technique to the paramedian anterior and middle cranial fossae: technical notes, anatomomorphometric quantitative analysis, and illustrative case
  31. Long-Term Perspectives on Chronic Rhinosinusitis with Nasal Polyps: Evaluating Recurrence Rates after Functional Endoscopic Sinus Surgery in the Biologics Era—A 5-Year Follow-Up Study
  32. Multidisciplinary Decision-Making—ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study)
  33. Perceptual, aerodynamic and acoustic outcomes of surgical technique for sulcus vocalis patients: A systematic review and meta analysis
  34. TIVA and TCI in Modern Anesthesia
  35. Normative data for interpreting the SNOT-22
  36. The Impact of Antibiotics and Steroids on the Nasal Microbiome in Patients with Chronic Rhinosinusitis: A Systematic Review According to PICO Criteria
  37. Chronic Rhinosinusitis with Nasal Polyps: A Survey on Routine Management and Evaluation of Disease Control in Practice
  38. High-Definition 3D Exoscope in Pediatric Otorhinolaryngology: A Systematic Literature Review
  39. Impatto della pandemia COVID-19 sull’otorinolaringoiatria pediatrica
  40. Raccomandazioni pratiche nella gestione ambulatoriale della rinosinusite cronica con poliposi nasale severa, nell’era dei biologici
  41. Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis
  42. Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life
  43. Normative values of the topological metrics of the structural connectome: A multi-site reproducibility study across the Italian Neuroscience network
  44. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real‐life study (DUPIREAL)
  45. Therapeutic Strategies to Prevent the Recurrence of Nasal Polyps after Surgical Treatment: An Update and In Vitro Study on Growth Inhibition of Fibroblasts
  46. Can patient-reported outcomes and inflammatory markers define endotype 2 in chronic rhinosinusitis without nasal polyps?
  47. La gestione del paziente con rinosinusite cronica e poliposi nasale in Italia: expert opinion sul percorso diagnostico-terapeutico
  48. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
  49. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology
  50. Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?
  51. Does a closed reduction improve aesthetical and functional outcome after nasal fracture?
  52. Systematic Review of Parotid Gland Sarcomas: Multi-Variate Analysis of Clinicopathologic Findings, Therapeutic Approaches and Oncological Outcomes That Affect Survival Rate
  53. Effects of the Silica Dust on the Nasal Mucosa of Ceramic Workers
  54. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
  55. The Role of Allergen-Specific Immunotherapy in ENT Diseases: A Systematic Review
  56. Reboot surgery for chronic rhinosinusitis with nasal polyposis: recurrence and smell kinetics
  57. Long-term outcomes and quality of life following parotidectomy for benign disease
  58. Survey on Use of Local and Systemic Corticosteroids in the Management of Chronic Rhinosinusitis with Nasal Polyps: Identification of Unmet Clinical Needs
  59. The Present and Future of Allergen Immunotherapy in Personalized Medicine
  60. Quantitative MRI Harmonization to Maximize Clinical Impact: The RIN–Neuroimaging Network
  61. Advances in chronic rhinosinusitis in 2020 and 2021
  62. Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19
  63. Correlation between olfactory function, age, sex, and cognitive reserve index in the Italian population
  64. Sensitization to Gibberellin-Regulated Protein (Peamaclein) Among Italian Cypress Pollen–Sensitized Patients
  65. Ceramic Workers and the Inflammatory Effects of the Silica Dust on the Nasal Mucosa Detected by Nasal Cytology: a Pilot Study
  66. Perioperative Management of Patients Affected by Ischemic Cardiomyopathy
  67. Allergen Immunotherapy management during vaccinations: An international survey
  68. Bilateral and Ipsilateral Central Neck Dissection in Total Thyroidectomy: a Long Term Comparison of Complications
  69. Nasal cytology identifies allergic rhinitis phenotypes for managing allergen immunotherapy in clinical practice
  70. Diagnostic performance of nasal cytology
  71. How to predict the outcome of septorhinoplasty? A normative study of ROE and FROI-17 scores
  72. Nasal expression of the vascular endothelial growth factor and its receptors is reduced by mepolizumab in chronic rhinosinusitis with nasal polyposis
  73. The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?
  74. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management
  75. Long-term omalizumab efficacy in allergic rhinitis
  76. Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis
  77. Mepolizumab Effectiveness and Allergic Status in Real Life
  78. Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction
  79. Diagnosis of Obstructive Sleep Apnea in Patients with Allergic and Non-Allergic Rhinitis
  80. The role of allergoids in allergen immunotherapy: from injective to sublingual route
  81. Eosinophilic lingual tonsillitis induced by sublingual immunotherapy: A case series
  82. Role of invariant natural killer t cells in patients with tonsillar hypertrophy: the tonsil as an immunological organ.
  83. Effects of paraprobiotic MIMLh5 in the treatment of chronic rhinopharyngitis
  84. Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications
  85. Biologics for chronic rhinosinusitis with nasal polyps
  86. Total Versus Completion Thyroidectomy: A Multidimensional Evaluation of Long-Term Vocal Alterations
  87. The spectrum of therapeutic activity of mepolizumab
  88. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes
  89. Size and shape of the inferior vena cava before and after a fluid challenge: a pilot study
  90. Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps
  91. Postoperative Pain Management
  92. Changes of NGF pathway in allergic rhinoconjunctivitis: A conjunctival allergen challenge study
  93. Therapeutic Applications of Capsaicin in Upper Airways
  94. Factors reducing omalizumab response in severe asthma
  95. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma
  96. Atrial Fibrillation in the Perioperative Period
  97. Relationship Between Autism And Nasal Cytology
  98. A survey on features of allergic rhinitis in children
  99. Characteristics of Candidates for Allergen Immunotherapy
  100. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy
  101. maxon motor launches innovative 040 mm,150 watt high power DC motor